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Homocystinuria, an inherited disorder associated with 
premature atherosclerosis, represents a severe form of 
methionine intolerance. To analyze the importance of 
milder forms of methionine intolerance in the genesis of 
vascular disease, the relation between provokable meth•
ionine intolerance and coronary artery disease was 
investigated. 
In a group of 138 men, aged 31 to 65 years (mean 
53), referred for cardiac catheterization, plasma homo•
cystine was measured before and 6 hours after an oral 
I-methionine load (0.1 g/kg). Thirty-nine subjects found 
to have normal coronary arteries had a mean post-load 
plasma homocystine level of 0.59 ± 0.37 I'moilliter. A 
criterion at the 95th percentile (1.64 SD above the mean) 
was selected and applied to the remaining 99 subjects 
with coronary artery disease (0.70 ± 0.68I'mollliter). 
Inherited disorders of metabolism have been demonstrated 
to predispose to the development of atherosclerotic heart 
disease. The best studied examples are the familial diseases 
of lipid metabolism (I). It is less well known that abnor•
malities in amino acid metabolism have also been implicated 
in the pathogenesis of vascular disease (2-4). 
Impaired metabolism of methionine caused by partial or 
complete deficiencies in any of several enzymes (5,6) and 
cofactors (7-10) leads to the accumulation of the athero-
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Sixteen (16%) of 99 subjects with coronary artery disease 
exceeded this level as compared with 1 (2 %) of 39 sub•
jects without coronary artery disease (p < 0.04). The 
risk of coronary artery disease in men with provokable 
methionine intolerance was increased sevenfold as esti•
mated by the odds ratio. By correlation matrix and mul•
tivariate regression analyses, provokable homocystine•
mia was predictive of coronary artery disease and was 
independent of tobacco smoking, hypertension, diabetes 
mellitus, serum cholesterol and age. 
It is proposed that men with mild methionine intol•
erance exposed to the high methionine content of the 
Western diet may develop intermittent homocystinemia 
and thus may be at greater risk for the development of 
coronary artery disease. 
(J Am Coil CardioI1985;6:725-30) 
genic amino acid, homocysteine* (Fig. 1). Endothelial dam•
age caused by infusion of homocysteine has been demon•
strated in animal studies (11, 12), although it may not be a 
consistent finding (13). Oral ingestion of methionine in pyr•
idoxine (vitamin B6)-deficient animal models has produced 
homocystinemia and vascular changes (14,15). In humans, 
homocysteine accumulation occurs in the autosomal reces•
sive disorder of methionine metabolism, homocystinuria. 
The homozygous form of cystathionine synthetase defi•
ciency is associated with a 9% incidence of myocardial 
infarction, a 38% incidence of thromboembolic phenomena 
and a 23% incidence of cerebrovascular and frequent pe•
ripheral vascular events (16,17). 
*Homocysteine (2-amino-4-mercaptobutyric acid) is a demethylated 
product of methionine which is capable of conversion to methionine in the 
animal body by a transmethylation reaction with choline, betaine, etc. 
Homocystine (4' ,4' -dithiobis-[2-aminobutyric acid]) is the oxidized di•
sulfide form of homocysteine. 
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Figure 1. Pathways of methionine metabolism. The important 
step in these pathways is the conversion of homocysteine to cys•
tathionine which is catalyzed by the enzyme cystathionine f3-syn•
thetase and its cofactor pyridoxal phosphate (Pi + PP). A TP = 
adenosine triphosphate; Bl2 = vitamin B12; THF = tetrahydrofolate. 
, Severe forms of homocysteine accumulation rapidly pro•
mote atherogenesis in the young, and it has been proposed 
(18) that milder forms of homocystinemia might act more 
slowly to cause atherosclerosis in adults. The population 
at risk includes at least 2 to 3 million Americans with partial 
cystathionine f3-synthetase deficiency (18), and others with 
different types of acquired or inherited abnormalities of 
methionine metabolism. 
In this study, we used an oral methionine load to study 
provokable methionine intolerance as measured by increased 
concentrations of plasma homocystine in men undergoing 
coronary arteriography. There was a significantly greater 
frequency of methionine intolerance in subjects with coro•
nary artery disease than in those without angiographic evi•
dence of atherosclerosis. We propose that methionine in•
tolerance may be a risk factor in the development of coronary 
artery disease. 
Methods 
Study subjects. All male patients aged 21 to 65 years 
undergoing clinically indicated cardiac catheterization at New 
York University-Bellevue Medical Center were eligible for 
this study. Subjects were included on the basis of investi•
gator availability at the time of admission for arteriography 
during the period from June 1981 to December 1982. Ninety•
six percent (n = 118) of the patients approached agreed to 
participate in this study. Informed consent was obtained as 
approved by the Institutional Review Committees for Hu•
man Research at the Medical Center. The 118 patients who 
agreed to participate had a preangiography diagnosis of ath•
erosclerotic heart disease, atypical chest pain, valvular heart 
JACC Vol. 6, No.4 
October 1985:725-30 
disease or cardiomyopathy. In addition, 20 male outpatients 
who were known to have angiographically normal coronary 
arteries from a previous catheterization also agreed to par•
ticipate in the study. 
Obligate heterozygotes. Eight male obligate heterozy•
gotes for cystathionine f3-synthetase deficiency who had 
children with homocystinuria were included as a subgroup 
with known methionine intolerance. This group did not 
undergo cardiac catheterization. 
Clinical data. Subjects were interviewed by one of two 
investigators (D.M.C. or M.W.) without knowledge of lab•
oratory results or cardiac catheterization data. Data were 
obtained on tobacco smoking history, hypertension, family 
history of atherosclerotic heart disease in first degree rela•
tives, gout, diabetes mellitus, history of hyperlipidemia, 
previous myocardial infarction, associated vascular disor•
ders, weight, height, dietary history, exercise pattern and 
present medications. Family history of coronary disease in 
first degree relatives was obtained but the age of onset of 
disease in these relatives was not available. 
Laboratory values for fasting blood glucose, transami•
nases, blood urea nitrogen, creatinine, alkaline phosphatase, 
lactic dehydrogenase, total bilirubin, fasting serum choles•
terol and triglycerides were obtained. All laboratory tests 
were performed using standard techniques in the Medical 
Center clinical laboratory . Results of routine admission elec•
trocardiograms and chest X-ray films were also obtained. 
Methionine load test. A control venous blood sample 
was obtained at approximately 9:00 AM after a 12 hour fast. 
L-methionine (0.1 g/kg) was then given orally in orange 
juice (19). Six hours later a venous blood sample was ob•
tained. Patients were allowed a light hospital lunch between 
samples. Heparinized blood samples were centrifuged im•
mediately at 5,000 g for 10 minutes. The plasma was re•
moved and precipitated with 50% sulfasalicylic acid (SSA) 
solution in a 10:1 plasma:SSA ratio. Specimens were cen•
trifuged at 5,000 g for 10 additional minutes and the su•
pernatant was stored at - 20° C. 
Samples were analyzed for methionine, homocysteine•
cysteine mixed disulfide and homocystine. Concentrated lith•
ium citrate buffer containing an internal standard, f3-alanine, 
was added (1 part to 11 parts sample). After centrifugation 
for 2 minutes at 14,000 g, an aliquot was loaded on a 
Beckman 119 CL automatic amino acid analyzer (Beckman 
Instruments). Amino acids were eluted with 0.2N lithium 
citrate buffers (pH 2.83 and 3.70) and the column was 
regenerated with 0.3N lithium hydroxide. The flow rate was 
44 mllmin. Change to the second buffer occurred at 40 
minutes, reequilibration required 20 minutes and regener•
ation buffer was added at 155 minutes. The starting tem•
perature was 45°C and was changed to 65°C at 85 minutes. 
Methionine elutes at 74 minutes, mixed disulfide at 90 min•
utes and homocystine at 160 minutes. The peak areas were 
integrated with a Spectrophysics 4000 analyzer. Limits of 
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detection of homocystine and homocysteine-cysteine mixed 
disulfide were approximately 0.01 j.tmollliter. 
Repeat methionine load tests on subjects were not per•
formed. Accuracy was checked by comparison with au•
thentic standards and demonstration that no ninhydrin-pos•
itive compounds co-eluted. Coefficients of variations for 
within run precision (I %, n == 10) and day to day precision 
(2%, n == 15) were determined by repetitive analysis of a 
human plasma sample. The laboratory investigators had no 
knowledge of clinical or catheterization data. 
Cardiac catheterization. Coronary arteriography was 
performed using standard catheterization techniques. Mul•
tiple left anterior oblique and right anterior oblique projec•
tions and hemiaxial views were obtained at the discretion 
of the attending cardiologists performing the test. Cinean•
giograms were recorded on 35 mm film. 
Films were analyzed independently by two investigators 
(E.G. and F.F.) who had no knowledge of the results of 
amino acid analyses. All major epicardial coronary arteries 
were evaluated and lesions were described as mild (10 to 
25% narrowing in luminal diameter), moderate (25 to 75% 
narrowing), severe (75 to 99% narrowing) or total obstruc•
tion. Only the severest lesion in each vessel was scored. 
Coronary artery disease was considered to be present if at 
least one severe lesion, two moderate lesions or more than 
three mild lesions were found; otherwise, the coronary ar•
teries were rated normal. In the case of disagreement as to 
the presence of disease, the films were reviewed by a third 
investigator and a consensus was obtained. 
Criterion for methionine intolerance. Plasma concen•
trations of homocystine after methionine loading in subjects 
with normal coronary arteries were used to calculate the 
95th percentile (1.64 SD above the mean) for the methionine 
tolerance test. All plasma homocystine concentrations above 
this level indicate methionine intolerance. The 95th per•
centile criterion was applied to the obligate heterozygote 
group to test its sensitivity. 
Statistical methods. Student's t test was used to assess 
differences between groups in clinical characteristics, mean 
amino acid concentrations and methionine doses. Two-tailed 
Fisher's exact test was used to evaluate the significance of 
the univariate odds ratios and to calculate the 95% confi•
dence intervals. Correlation coefficients were calculated to 
analyze associations among variables. Multivariate logistic 
regression analysis was performed to control for confound•
ing factors and to estimate the adjusted odds ratios. 
Results 
The study patients (n == 138) were grouped into 39 men 
with normal coronary arteries (noncoronary group) and 99 
men with coronary artery disease (coronary group). In the 
normal noncoronary group, there were no significant dif•
ferences in clinical characteristics or amino acid concentra-
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Table 1. Clinical Characteristics for 138 Male Subjects 
Noncoronary Coronary 
Group Group 
Mean age (yr) 52 ± 8 53 ± 8 
Mean weight (kg) 76 ± 9.9 82.5 ± lit 
% Tobacco smoking 36 60* 
% Hypertension 15 40* 
% Diabetes mellitus 8 13 
% Family history 44 58 
% Prior myocardial 0 60* 
infarction 
% Other vascular disease 0 26 
Serum cholesterol (mg/dO 222 ± 36 250 ± 64 
(n = 14) (n = 66) 
Unless noted, n = 39 for the noncoronary group, n = 99 for the 
coronary group. *p < 0.05 and tp < 0.01; otherwise there was no sig•
nificant difference. Student's t test was used to compare the significance 
of the differences between groups. 
tions between outpatients and inpatients. Clinical charac•
teristics for all subjects are summarized in Table 1. 
By convention, the 95th percentile for homocystine con•
centrations after methionine loading was determined in the 
normal (noncoronary) group to define methionine intoler•
ance. Of the obligate heterozygotes, 87% (seven of eight) 
were correctly identified using this calculation (Fig. 2). 
Univariate and multivariate analyses. Of the coronary 
group, 16% (16 of 99) were methionine intolerant compared 
with 2% (1 of 39) of the noncoronary group (Fig. 2). This 
difference was statistically significant (p < 0.04). The uni-
Figure 2. Post-load plasma homocystine concentrations in the 
three patient groups. The plasma homocystine concentration for 
each subject is plotted on the graph by its respective group. The 
dotted line represents the 95th percentile level of homocystine for 
the group with normal coronary arteries (see text). This level was 
calculated as 1.64 x SD above the group mean and is equal to 
1. 19 ILmol/liter. Concentrations above this level represent methi•
onine intolerance. 
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variate analysis of methionine intolerance as a risk factor 
for coronary artery disease yielded an odds ratio of 7.3 (95% 
confidence interval: 1.05 to 315) indicating a sevenfold in•
creased risk for coronary artery disease. 
To control for possible confounding variables, correla•
tion matrix and logistic regression analyses were performed. 
There were no significarit correlations among plasma ho•
mocystine and serum cholesterol, diabetes mellitus, family 
history, cardiac medications, weight, height, cigarette smoking 
(>25 pack-years), hypertension, exercise, cardiac output, 
body mass index or age. A logistic model showed that none 
of the known risk factors were important confounding fac•
tors because there was little change in the odds ratio of 
methionine intolerance (6.7 by multivariate analysis com•
pared with 7.3 by univariate analysis). The magnitude of 
the association between methionine intolerance and coro•
nary artery disease was unchanged; however, fragmentation 
of a relatively small number of subjects among different 
variables changes the signficance of the relation (p = 0.09). 
This was expected in a study of this size. The odds ratio of 
methionine intolerance is higher than that of all other vari•
ables including cigarette smoking (3.5) and hypertension 
(4.0); however, its effect ori variance is less than that of 
these other factors because it occurs less frequently in the 
study group. 
Amino acid concentrations from methionine load test•
ing (Table 2). There were rio significant differences in the 
mean concentrations of methionine, homocysteine-cysteine 
disulfide or homocystine concentrations for heterozygotes 
and noncoronary and coronary groups before methionine 
loading. Methionine concentrations after loading were in•
creased above baseline levels, but there were no significant 
differences among heterozygotes and noncoronary or coro•
nary groups. Concentrations of mixed homocysteine•
cysteine disulfide after loading were lower in the noncor•
onary group than in the coronary group and highest in the 
heterozygotes. A significant differences was found between 
the obligate heterozygotes and the noncoronary group; how•
ever, there is considerable overlap in individual values 
(Fig. 3). 
Table 2. Amino Acid Analysis (mean ± SD JLmollliter) 
Post-load 
Heterozygotes 
Noncoronary group 
Coronary group 
Preload 
Heterozygotes 
Noncoronary group 
Coronary group 
Methionine 
16.35 ± 9.01 
20.25 ± 4.68 
20.53 ± 7.53 
396 ± 197.2 
483.3 ± 141.9 
537.5 ± 165.0 
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Plasma homocystine concentrations after methionine 
loading were lowest in the noncoronary group and signifi•
cantly different from values in the heterozygotes. The mean 
concentration in the coronary group was higher than that in 
the noncoronary group. As expecte!l in the two groups (non•
coronary versus coronary) with low prevalence of this bio•
chemical trait and relatively small sample size, comparison 
of mean values alone showed a trend toward a higher mean 
homocystine concentration that did riot reach statistical 
significance. 
Analysis of other potential confounding factors. The 
methionine dose was determined by body weight; therefore, 
the mean grams of methionine given per kilogram were the 
same for the coronary and noncoronary groups. In the anal•
ysis, the mean grams of methionine given per square me•
ter of body surface area were computed and found to dif•
fer between the two groups (4.0 ± 0.3 versus 4.2 ± 0.3, 
mean ± SD) (p < 0.01). This difference occurred because 
patients in the coronary group weighed more than those in 
the noricoronary group. The mean grams of methionine given 
per square meter did not differ between methionine-intol•
erant and methionine-tolerant subjects within the coronary 
group (4.2 ± 0.3). In addition, when obese subjects were 
excluded from the analysis ori the basis of body mass index 
greater than 30 kg/m2 (the 95th percentile in the control 
group) and the univariate analysis was repeated, the odds 
ratio for methionine intolerance remained essentially the 
same (6.8, p < 0.05 versus 7.3, p < 0.04). 
To assess the effect of the arteriographic scoring system 
on the data, stricter criteria were applied (normal coronary 
arteries defined as those with less than one moderate lesion) 
and the data were analyzed again. The number of subjects 
in the coronary and the noncoronary group was unchanged 
arid the results remained the same. 
Discussion 
The autosomal recessive disorder of methionine metab•
olism, homocystinuria, was first described in 1962 by Car•
son and Neill (20). The clinical manifestations of the homo-
Mixed Disulfide 
2.26 ± 1.04 
2.73 ± 1.11 
3.22 ± 2.07 
14.62 ± 6.46} 
9.39 ± 3.67 * 
10.47 ± 5.16 
Homocystine 
0.00 ± 0.00 
0.06 ± 0.12 
0.03 ± 0.1/ 
2.50 ± 1.07} 
0.59 ± 0.37 t 
0.70 ± 0.68 
* p < 0.05 and t p < 0.001, otherwise there were no significant differences between groups when comparing heterozygote versus noncoronary 
groups or non coronary versus coronary groups using Student's t test. 
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Figure 3. Post-load plasma mixed homocysteine-cysteine disul•
fide in the three patient groups. The plasma mixed disulfide con•
centration for each subject is plotted on the graph by its respective 
group. The dotted line represents the 95th percentile level of mixed 
disulfide for the group with normal coronary arteries (see text). 
This level was calculated as 1.64 X SO above the group mean 
and is equal to 15 Al JLmollliter. 
zygote state of this disease include premature atheroscle•
rosis, thromboembolic phenomena and ocular and mus•
culoskeletal abnormalities, Since the original description of 
homocystinuria, the atherogenic potential of the sulfur amino 
acid homocysteine has been investigated, In most animal 
studies (11-13), the administration of homocystine has been 
associated with the development of atherosclerotic lesions, 
In endothelial cell and smooth muscle cell cultures (21), the 
cytotoxicity of homocysteine has been shown to be con•
centration dependent. 
Pathophysiology of homocystinemia. The pathophys•
iology of the homocysteine-vessel wall interaction is thought 
to be a multifaceted process (22) that involves 1) direct 
chemical injury to the endothelium, 2) disruption of the 
elastic lamina due to a sulfhydryl reaction with lysyl al•
dehyde that prevents cross-linking of elastin, 3) precipitation 
of highly sulfated lipoprotein-proteoglycan complexes within 
the vessel wall, 4) increased synthesis of thromboxane A2 , 
and 5) decreased platelet survival time, Deficiencies of any 
one of several enzymes or cofactors in the pathway of meth•
ionine metabolism can be responsible for increased con•
centrations of plasma homocystine, Cystathionine {3-syn•
thetase (6), pyridoxal phosphate (7), folate, vitamin BI2 (8), 
methylene tetrahydrofolate reductase (23) and methyl trans•
ferase (24) have each been shown to cause homocystinemic 
states, These metabolic defects have been associated with 
atherosclerosis in humans and experimental animal models, 
Choice of control group. We and other investigators 
(25-29) have used an oral methionine load test as a non•
specific challenge of methionine metabolism. The standard 
oral load of methionine has been shown (25) to cause in•
creased concentrations of plasma homocystine in hetero-
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zygotes for cystathionine (3-synthetase deficiency when 
compared with values in control subjects. The methionine 
loading dose is four times greater than the average daily 
methionine ingestion, but it is used to stress the pathway 
and not to simulate daily intake. The normal range for this 
test in the general population has never been studied. A 
conventional criterion of the 95th percentile level of post•
load plasma homocystine was adopted as the upper limit of 
normal in our patients with noncoronary disease. We pre•
ferred a control group with angiographically proven normal 
coronary arteries instead of one without clinical evidence 
of coronary disease because such a control group could have 
asymptomatic coronary disease in as many as 40% of the 
sample size (30). We accept the limitation that our control 
group is not truly representative of the general population; 
however, an angiographically controlled study allows an 
assessment of risk factors in patients with well defined dis•
ease or no disease. 
Findings and limitations. Our findings are consistent 
with the hypothesis that methionine intolerance is a risk 
factor for coronary disease. We found that 16 (16%) of 99 
patients in our coronary group compared with only I (2%) 
of 39 in the noncoronary group had evidence of methionine 
intolerance. This association was independent of the other 
cardiac risk factors studied. Our data showed a sevenfold 
increased risk for developing cornary artery disease as a 
function of methionine intolerance. We did not expect to 
demonstrate that the extent of coronary disease was corre•
lated with the concentration of homocystine because of the 
small sample size and the time-dependent, multifactorial 
nature of atherogenesis. It is important to recognize that the 
conclusions from this study must be construed not as proof 
that methionine intolerance causes atherosclerosis but rather 
as consistent with this hypothesis. The data are limited by 
the relatively small sample size and the lack of repeat meth•
ionine load testing of the subjects to verify the reproduc•
ibility of their results. However, this study is the largest 
clinical investigation of the methionine intolerance hypoth•
esis to date, and the first study to consider the interaction 
of the other risk factors in a multivariate model. All previous 
studies using the methionine load test (26,28,29), with one 
exception (27), have supported this hypothesis. 
Potential significance and implications. The popula•
tion that may be at risk to develop coronary artery disease 
from abnormal methionine intolerance has been estimated 
to be as large as 4 to 5 million people in the United States 
alone (22). If this group ingests large quantities of protein, 
typical of the Western diet, they might have sufficient in•
termittent accumulations of homocystine to damage endo•
thelium and incite the development of atherosclerosis. We 
recognize that atherosclerotic vascular disease is a multi•
factorial disorder in which methionine intolerance may only 
contribute a small risk. However, if methionine intolerance 
can be identified early in life, it can be potentially modified 
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before the development of clinically significant vascular 
disease. It has been shown in some cases (16) that the 
administration of oral pyridoxine improves the metabolism 
of methionine in patients with cystathionine l3-synthetase 
deficiency. Therefore, vitamin therapy is a potential avenue 
for decreasing cardiovascular risk associated with this met•
abolic abnormality. In addition, it has been shown in the 
baboon model that the administration of dipyridamole or 
sulfinpyrazone protects the endothelium during homocys•
teine infusion (3,31). The use of antiplatelet drugs or pros•
taglandin inhibitors might represent a second therapeutic 
modality. Finally, our data suggest another reason for rec•
ommendation of the prudent low cholesterol diet proposed 
by the American Heart Association-because it is also rel•
atively low in methionine content. However, a proof of our 
methionine intolerance hypothesis must be obtained before 
considering any therapeutic or preventative trials. 
Conclusions. We have presented data that are consistent 
with the hypothesis that methionine intolerance is a risk 
factor in coronary artery disease. Previous in vitro and in 
vivo investigations demonstrated that homocystine is an ath•
erogenic amino acid. We have speculated that men with 
mild methionine intolerance will develop intermittent ho•
mocystinemia and consequent endothelial damage that could 
predispose to the development of atherosclerotic disease. 
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